324 related articles for article (PubMed ID: 21912640)
21. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
[TBL] [Abstract][Full Text] [Related]
22. Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma.
Cheng HY; Kang PJ; Chuang YH; Wang YH; Jan MC; Wu CF; Lin CL; Liu CJ; Liaw YF; Lin SM; Chen PJ; Lee SD; Yu MW
PLoS One; 2014; 9(11):e95870. PubMed ID: 25427199
[TBL] [Abstract][Full Text] [Related]
23. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
[TBL] [Abstract][Full Text] [Related]
24. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.
Calderaro J; Rousseau B; Amaddeo G; Mercey M; Charpy C; Costentin C; Luciani A; Zafrani ES; Laurent A; Azoulay D; Lafdil F; Pawlotsky JM
Hepatology; 2016 Dec; 64(6):2038-2046. PubMed ID: 27359084
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B.
Wenjin Z; Chuanhui P; Yunle W; Lateef SA; Shusen Z
BMC Gastroenterol; 2012 Aug; 12():109. PubMed ID: 22894700
[TBL] [Abstract][Full Text] [Related]
26. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
27. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.
Shi F; Shi M; Zeng Z; Qi RZ; Liu ZW; Zhang JY; Yang YP; Tien P; Wang FS
Int J Cancer; 2011 Feb; 128(4):887-96. PubMed ID: 20473887
[TBL] [Abstract][Full Text] [Related]
28. Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.
El-Gebaly F; Abou-Saif S; Elkadeem M; Helmy A; Abd-Elsalam S; Yousef M; Elkhouly RA; Amer IF; El-Demerdash T
Curr Cancer Drug Targets; 2019; 19(11):896-905. PubMed ID: 31538897
[TBL] [Abstract][Full Text] [Related]
29. Association of Increased Programmed Death Ligand 1 Expression and Regulatory T Cells Infiltration with Higher Hepatocellular Carcinoma Recurrence in Patients with Hepatitis B Virus Pre-S2 Mutant after Curative Surgical Resection.
Jeng LB; Li TC; Hsu SC; Teng CF
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746817
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
Front Immunol; 2018; 9():2077. PubMed ID: 30254644
[No Abstract] [Full Text] [Related]
31. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection.
Itoh S; Yugawa K; Shimokawa M; Yoshiya S; Mano Y; Takeishi K; Toshima T; Maehara Y; Mori M; Yoshizumi T
BJS Open; 2019 Aug; 3(4):500-508. PubMed ID: 31388642
[TBL] [Abstract][Full Text] [Related]
33. ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma.
Iseda N; Itoh S; Yoshizumi T; Yugawa K; Morinaga A; Tomiyama T; Toshima T; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Apr; 5(4):675-688. PubMed ID: 33860125
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.
Gabrielson A; Wu Y; Wang H; Jiang J; Kallakury B; Gatalica Z; Reddy S; Kleiner D; Fishbein T; Johnson L; Island E; Satoskar R; Banovac F; Jha R; Kachhela J; Feng P; Zhang T; Tesfaye A; Prins P; Loffredo C; Marshall J; Weiner L; Atkins M; He AR
Cancer Immunol Res; 2016 May; 4(5):419-30. PubMed ID: 26968206
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of PD-L1 in Patients with Hepatocellular Carcinoma.
Pei R; Zhang W; Wang S; Huang X; Zou Y
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115210
[TBL] [Abstract][Full Text] [Related]
36. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
Liu CQ; Xu J; Zhou ZG; Jin LL; Yu XJ; Xiao G; Lin J; Zhuang SM; Zhang YJ; Zheng L
Br J Cancer; 2018 Jul; 119(1):80-88. PubMed ID: 29921949
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical expression of immune check point protein PDL-1 in hepatocellular carcinoma denotes its prognostic significance and association with survival.
Helmy DO; Khattab F; Hegazy AE; Sabry RM
J Immunoassay Immunochem; 2023 May; 44(3):213-228. PubMed ID: 36281205
[TBL] [Abstract][Full Text] [Related]
38. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma.
Mocan T; Ilies M; Nenu I; Craciun R; Horhat A; Susa R; Minciuna I; Rusu I; Mocan LP; Seicean A; Iuga CA; Hajjar NA; Sparchez M; Leucuta DC; Sparchez Z
Int Immunopharmacol; 2021 May; 94():107467. PubMed ID: 33611059
[TBL] [Abstract][Full Text] [Related]
39. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.
Zhang J; Fang W; Qin T; Yang Y; Hong S; Liang W; Ma Y; Zhao H; Huang Y; Xue C; Huang P; Hu Z; Zhao Y; Zhang L
Med Oncol; 2015 Mar; 32(3):86. PubMed ID: 25702326
[TBL] [Abstract][Full Text] [Related]
40. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma.
Dong ZZ; Yao DF; Yao M; Qiu LW; Zong L; Wu W; Wu XH; Yao DB; Meng XY
Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):288-95. PubMed ID: 18522884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]